| :: lorus therapeutics |
TORONTO - Lorus Therapeutics Inc. (TSX:LOR), a small Toronto biopharmaceutical company, made a big move on the stock market Monday
Lorus Therapeutics Inc (LOR) - Financial and Strategic Analysis Review Lorus Therapeutics Inc. (Lorus) is a life sciences company engaged
LORUS THERAPEUTICS AKTIE | Aktienkurs | Nachrichten zur Aktie Lorus Therapeutics Inc | A1CZ5P | | CA5441923052.
TORONTO - Cancer drug developer Lorus Therapeutics Inc. (TSX:LOR) cut its annual operating losses for the fiscal 2011 year ended May 31.
Lorus Therapeutics Provides Update on Offering of Units.
8, 2011) - Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), today announced the presentation of positive nonclinical toxicity data for its lead small
Lorus Therapeutics, Inc. About Us Lorus is a Canadian biopharmaceutical company specialising in the research, development and commercialisation of
Lorus Therapeutics Announces Patent Allowance for Lead Small Molecule Drugs [May 18, 2010 - 05:27 AM PST]: Lorus Therapeutics
Stock market news and stock research. Financial news, stock news and stock makrket update about the stocks, ETF and mutual funds listed on the NYSE, AMEX
Lorus Therapeutics Announces Presentation of New Preclinical Data for Anticancer Drug LOR-253 at the American Association for Cancer
Lorus Therapeutics Inc. 11-21 successfully develop cancer therapeutics that satisfy its mission. Lorus has three platform technologies from which its four lead
Lorus Therapeutics Inc. announces the presentation by investigators at Ohio State University (OSU) of results for Lorus' lead clinical drug candidate LOR-2040 ,
Sponsor: Lorus Therapeutics. Collaborators: Wake Forest University University of Chicago. Information provided by: Lorus Therapeutics
Lorus Therapeutics Inc. (“Lorus”) today announced that it has renewed an emergency drug program to supply its anticancer product, Virulizin(R) for the treatment
Lorus Therapeutics Inc. announced Monday that its two lead anti-cancer drugs, GTI-2040 and GTI-2501, showed significant anti-tumor activity
Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development
Lorus Therapeutics Presents Positive Data From Nonclinical Toxicity Studies on Lead Cancer Drug at Major Conference [November 8, 2011
Business Editors TORONTO--(BUSINESS WIRE)--June 13, 2000 [pilcrow ( paragraph sign)] Excellent Pre-clinical Results of Gti-2501, Patent
Lorus recognizes the urgency in addressing the need for safe and effective cancer therapies, and is committed to advancing our drug pipeline expeditiously
EN: 277748. ABSTRACT. LOR-2040 (formerly GTI-2040), an antisense oligonucleotide (ASO) developed by Lorus Therapeutics, is currently undergoing clinical
Lorus Therapeutics Announce Board of Directors Approval of 1-for-30 Share Consolidation · PDF, Print, E-mail . Stocks To Watch. 0; 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 11
The organizational chart of Lorus Therapeutics displays its 10 main executives including Aiping Young, Elizabeth Williams and Peter Murray.
Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), today announced the presentation of positive nonclinical toxicity data for its lead small molecule
Grace Tse, Lorus Therapeutics Inc., Etobicoke, ON - Business Contact Information in Jigsaw's business directory. Jigsaw's business directory provides complete
TORONTO (Feb. 9) BUSINESS WIRE- Feb. 9, 1999-- Lorus Therapeutics I ( NASDAQ:LORFF)(TSE:LOR.)(ME:LOR.) Novel anti-cancer
TORONTO--(BUSINESS WIRE)--Dec. 7, 1999-- (TSE:LOR.) (ME:LOR.) (OTCBB: LORFF) Lorus Therapeutics Inc. (
Lorus is a Canadian biopharmaceutical company specialising in the research, development and commercialisation of pharmaceutical products and
Lorus Therapeutics. 12/28/2011, 4:20 AM ET. Quotes; Dashboard · Chart · Historical Prices · Options. Analysis; Focus Articles · Related Articles · Instablogs
Welcome to the company profile of Lorus Therapeutics on LinkedIn. Lorus Therapeutics, Inc., a biopharmaceutical company, engages in the research and
Lorus Therapeutics Completes Acquisition Of GeneSense Technologies Inc from Business Wire.
Lorus Therapeutics Inc files 20-F (Annual and transition report of foreign private issuers) SEC Filing.
TORONTO, July 10, 2007 PRNewswire-FirstCall - Lorus Therapeutics Inc. , a biopharmaceutical company specializing in the research and
New Phase I Study from Lorus Therapeutics (Jan. 16/11). The biotech company Lorus has announced the enrollment of the first cancer patient
Lorus Therapeutics. Orr RM. CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK. rosanne@icr.ac.uk. Loris Therapeutics
Oncogene is one of the world's leading cancer journals.
Lorus Therapeutics stock prices by StockNod. Current LRP stock price by day and historical Lorus Therapeutics stock prices by month, quarter, and year for
Lorus Therapeutics Inc. is a biopharmaceutical company focused on the discovery, research and development of effective anticancer therapies with high safety
Lorus Therapeutics Inc. (“Lorus”) is a biopharmaceutical company specializing in the research, development, and commercialization of
He is currently a director of Trinity Biotech PLC, a diagnostic products developer, and Lorus Therapeutics, a cancer therapeutics company. Earlier in his career,
Many Lorus Therapeutics, Inc. products on Amazon and other vendors for best prices!
T.LOR Lorus Therapeutics Inc. Lorus Therapeutics Reports First Quarter Results for Fiscal 2012 11/11/2011 4:00:12 PM - Market Wire. Lorus Therapeutics
Results 1 - 29 The article reports on the allowance of Lorus Therapeutics Inc.'s first patent in China for novel drug candidates from its small molecule program.
LORUS THERAPEUTICS INC. Patent applications. Patent application number, Title, Published. 20110158936, USE OF INTERLEUKIN 17E FOR THE
TORONTO, ONTARIO, Oct 21, 2010 (Marketwire via COMTEX News Network) -- Lorus Therapeutics Inc. (TSX:LOR)(OTCBB:LRUSF) ("Lorus"),
TORONTO, July 21 /PRNewswire-FirstCall/ -- Lorus Therapeutics Inc.
13, 2011) - Lorus Therapeutics Inc. (TSX:LOR)(OTCBB:LRUSF) ("Lorus"), a biopharmaceutical company specializing in the discovery, research
Lorus Therapeutics Inc-Deals & Alliances Report, published March 2011, pages 44, Lorus Therapeutics Inc-Deals & Alliances ReportReport contains the
Detailed Share Price, Charts and News for Lorus Therapeutics Inc [TSE,LOR]. Share Market Tools for Successful Investing. Global Share
Lorus Therapeutics Inc (LOR) - Financial and Strategic SWOT Analysis Review Lorus Therapeutics Inc (LOR) - Financial and Strategic SWOT
Mario Huesca, Lorus Therapeutics Inc., Etobicoke, ON - Business Contact Information in Jigsaw's business directory. Jigsaw's business directory provides
Lorus Therapeutics Inc. (Lorus) is a life sciences company engaged in the discovery, research and development of efficacious and safe anticancer thera.
From 2000 to 2003 he was Vice President Finance and Administration at Lorus Therapeutics Inc. a TSX listed company. Mr. Parsons holds a Bachelor of Arts
Hoovers company profile of Lorus Therapeutics Inc.. Find detailed business information Lorus Therapeutics isn't talking nonsense, they're talking antisense .
Free chart and quote for Lorus Therapeutics Inc. (LRUSF). Technical indicators, studies, real time charts.
Correspondence to Dr Yoon Lee, PhD, Lorus Therapeutics Inc., 2 Meridian Road, . Toronto, Ontario, Canada M9W 4Z7. Tel: +416 798 1200; fax: +416 798 2200;
LOR-253 (formerly LT-253) is currently being developed by Lorus Therapeutics. LOR-253 is a first-in-class inhibitor of the Metal Transcription Factor-1 (MTF-1)
Get to know LORUS THERAPEUTICS INC (LOR:CN) CEO & other corporate executives. Learn about the Board of Directors, Executive
Verified on January 2011 by Lorus Therapeutics. First Received Further study details as provided by Lorus Therapeutics: Primary Outcome
Health care industry insiders provide analysis & data on pharma biotech device & diagnostic company strategy & trends. Deals & technology
13, 2012) - Lorus Therapeutics Inc. (TSX:LOR) ('Lorus' or the 'Corporation'), a biopharmaceutical company specializing in the research and
News for Medical Sales & Marketing professionals and Independent Sales Representatives: Lorus Therapeutics Files Investigational New Drug
Lorus Therapeutics (TSX:LOR) has closed a private placement of 1581667 common shares at a price of $1.05 each for gross proceeds of
Home | Login | Stockstream. Lorus Therapeutics Inc. lor go to snapshot add to favorites. post. see all posts, Overall Quality 2+, Overall Quality 3+, Overall Quality
Market Research, TF Market Research: LORUS THERAPEUTICS INC- COMPANY INSIGHT - LIFE SCIENCE ANALYTICS - 2010/01/08
(Retired, 30 March 2007). 2310 Alfred-Nobel Blvd. St-Laurent, QC. Canada H4S 2A4. 1998 - 2000. Director of Preclinical Development. Lorus Therapeutics, Inc.
Lorus Therapeutics Provides Corporate Update. Submitted by 30, 2011) - Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"),
Stock analysis for LOR:CN. Get stock price, historical stock charts & news for Lorus Therapeutics Inc, in the Medical-Biomedical/Gene industry.
Lorus Therapeutics Presents Positive Data From Nonclinical Toxicity Studies on Lead Cancer Drug at Major Conference
Locations. Address. Lorus Therapeutics, Incorporated 2 Meridian Road Toronto, Ontario M9W 4Z7 Canada. Phone: 416-798-1200; Email
LORUS THERAPEUTICS Aktie im Überblick: Kurs, Realtimekurs und Chart. Nachrichten und Diskussionen zu LORUS THERAPEUTICS (CA5441921072,
Company profile for Lorus Therapeutics. Includes latest key event, news and commentary, top selling products, worldwide prescription sales, sales by therapy
Lorus Therapeutics Inc. 2 Meridian Rd Toronto, ON M9W 4Z7 Tel: (416) 798- 1200. Fax: (416) 798-2200. Contact Name Elizabeth Williams. Industry 35201010 -
Lorus Therapeutics Inc. (TSX:LOR) (Lorus or the Corporation), a biopharmaceutical company specializing in the research and development of
LORUS THERAPEUTICS ANNOUNCES ELECTION OF THREE NEW DIRECTORS AND APPOINTS A NEW CHAIRMAN (9/20/2007) LORUS
From 2001 to 2002, he served as President and Chief Operating Officer of Lorus Therapeutics, Inc., a biopharmaceutical company. From 1987 to 2001, Dr.
Lorus Therapeutics Inc. (“Lorus”) announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for Virulizin in the
Symbol: LOR:CA, Name: Lorus Therapeutics Inc., Title: Lorus Therapeutics Inc. ( LOR:CA) Stock Quote.
Lorus Therapeutics Inc is a biopharmaceutical company focused on the discovery, research and development of novel therapeutics in cancer.
Send us Feedback. Lorus Therapeutics (LRP). Analysis. SUMMARY · BULLS · BEARS · TOPICS · DATA CENTRAL. STOCK CHART. Financials. SEC FILINGS
News and bulletins about Lorus Therapeutics for biotechnology, life sciences, pharmacy, healthcare, diagnostics, bioinformatics, updated daily and relevant to
Lorus Therapeutics Inc. (TSX: LOR; PINK SHEETS: LRUSF) has appointed of Warren Whitehead to its board of directors. Whitehead will also
Prior to joining, Dr. Babaei was Vice President, Business Development at Lorus Therapeutics where, as a member of their executive committee, he was
Lorus Therapeutics has started patients enrollment into a dose-escalation phase I trial of its cancer drug, LOR-253, to establish its safety and
Lorus Therapeutics LRP company news, announcements, releases, reports results & notices.
Lorus Therapeutics has received a new patent from the US Food and Drug Administration (FDA) for cancer drug LOR-2040, indicated for the
Lorus Therapeutics: Lorus carries out basic drug discovery research but also seeks to reduce the risks associated with early research by acquiring promising
On May 4, 2004 Lorus Therapeutics Inc. reported that it had initiated a clinical trial of GTI-2040 involving patients with advanced unresectable
Lorus Therapeutics and Ohio State U Partner on Nanoparticle Delivery of siRNA Cancer Rx. March 25, 2009. By Ben Butkus. Type size: - +; View on one page
Lorus Therapeutics Inc - 6-K - For 5/31/07 - EX-99.3 - Report of a Foreign Private Issuer - Seq. 4 - Annual Information Form - Accession Number
Lorus Therapeutics, Inc. Go Back. Organization: Lorus Therapeutics, Inc. About Us Lorus is a Canadian biopharmaceutical company specialising in the research
Lorus Therapeutics. (posted on 01/01/2006). Lorus is a Canadian biopharmaceutical company specialising in the research, development and commercialisation
Case study: LOR-2040 (Lorus Therapeutics) Antisense Case study: OGX-011 ( Isis Pharmaceuticals/OncoGenex) & LY2181308 (Isis Pharmaceuticals/Eli Lilly)
Lorus Therapeutics granted patent for clinical stage cancer drug TORONTO - Biopharmaceutical company Lorus Therapeutics Inc. (TSX:LOR), says the U.S.
View the basic LOR.TO stock chart on Yahoo! Finance. Change the date range, chart type and compare LORUS THERAPEUTICS INC. against other companies.
In 2010, the therapeutic cancer vaccine market witnessed several key NovaRX's Lucanix and Lorus Therapeutics/Zor Pharma's Virulizin.
TORONTO, ONTARIO -- (Marketwire) -- 01/13/12 -- Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Corporation"), a biopharmaceutical
Get Lorus Therapeutics Inc. business contacts for Healthcare,
LORUS THERAPEUTICS INC. (the Company). MRRS DECISION DOCUMENT. Background. The local securities regulatory authority or
11, 2011) - Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the discovery,
Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the discovery, research and
Lorus Therapeutics Inc. (TSX: LOR; PINK SHEETS: LRUSF) has filed a preliminary short-form base shelf prospectus and it may raise up to $15
Biotech / Medical: Lorus Therapeutics Inc. 276, News: Monday April 10, 9:05 pm Eastern Time Company Press Release Lorus Th · Zardoz, -, 04/11/2000 02: 10
Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research,
Lorus Therapeutics, Inc. latest news. Quickly understand and learn about Lorus Therapeutics, Inc. from your favorite sources with BuzzBox.
TORONTO, ONTARIO--(Marketwire - April 7, 2011) - Lorus Therapeutics Inc. ( TSX:LOR)(PINK SHEETS:LRUSF) ('Lorus'), a biopharmaceutical
VIRULIZIN Lorus Therapeutics partnering opportunity, Worldwide (pancreatic cancer).(Brief Article) - Find R & D Focus Drug News articles.
Lorus Therapeutics Inc. (LRP) Wall Street Analyst Forum September 9, 2008 11: 50 AM ET. Moderator. Good morning ladies and gentlemen.
IntelliPharmaCeutics International Inc. I. Isotechnika Pharma Inc, ISA. LAB Research Inc. LRI. Labopharm Inc. DDS. Lorus Therapeutics Inc. LOR. MDS Inc. MDS
Lorus Therapeutics Incorporated operates in the Biological products exc. diagnostic sector. Lorus Therapeutics Inc. is a biopharmaceutical company focused on
Lorus Therapeutics Inc. financial and business news, updates, and information from The New York Times and other leading providers.
Lorus Therapeutics Announces Allowance of Australian Patent for Clinical Cancer Drug LOR-253 [September 27, 2011 - 05:00 AM PST]:
Lorus Therapeutics Inc. (TSX: LOR) today provided updates to its Annual General and Special Meeting (AGM) of its shareholders held in
Lorus Therapeutics announces third clinical trial with GTI-2040 in 15 /CNW/ - Lorus Therapeutics announced today that approval has been
Lorus Therapeutics (approx. market cap C$ 4 mil.), a biopharmaceutical company, focuses on the discovery, research, and development of
Lorus Therapeutics Inc - Product Pipeline Review - H2 2011 Lorus Therapeutics Inc - Product Pipeline Review - H2 2011 Summary Global
Lorus Therapeutics Inc.'s quality control information - LOR-253, LOR-264 and View more quality control details from Lorus Therapeutics Inc. (16467918).
Lorus Therapeutics Inc. (Lorus), Toronto, a biopharmaceutical company specializing in the research, development and commercialization of
Lorus Therapeutics Enrolls First Patient in Phase I Clinical Study of 13, 2011) - Lorus Therapeutics Inc. (TSX:LOR)(OTCBB:LRUSF) ("Lorus"),
LORUS THERAPEUTICS INC (LOR:CN) stock price & investing information. Find LORUS THERAPEUTICS INC historical stock quotes, key competitors, stock
Lorus Therapeutics (TSX:LOR; OTCBB:LRUS.F) is putting the pedal to the metal and gearing up for a pivotal clinical trial by early 2011 and a
Lorus Therapeutics Inc. (LRP) Files Final Prospectus for Rights Offering to Shareholders Lorus Therapeutics Inc. (LRP) Reports Results for Fiscal Year 2010
SC 13G - Lorus Therapeutics Inc - On 2/27/06 - Statement of Beneficial Ownership - Seq. 1 - Accession Number 0001178913-06-000362
Lorus Therapeutics Presents Positive Data From Nonclinical Toxicity Studies on Lead Cancer Lorus Therapeutics granted patent for clinical stage cancer drug
Lorus Therapeutics Reports First Quarter Results for Fiscal 2012. Nov 8, 2011. Lorus Therapeutics Presents Positive Data From Nonclinical Toxicity Studies on
TORONTO, ONTARIO--(Marketwire - Aug. 15, 2011) -
Zor Pharmaceuticals LLC, Zor Pharmaceuticals has a licensing agreement with Lorus Therapeutics to develop and commercialize Virulizin® for human
Kiadis Pharma; Lorus Therapeutics, Inc.; Methylgene, Inc.; Migenix;
Lorus Therapeutics, Inc. XTSE:LOR Stock - Get Annual Report SEC Filing of Lorus Therapeutics, Inc. XTSE:LOR stocks, including company
Lorus Therapeutics announced positive results of a phase III trial of Virulizin for the Virulizin Virulizin (Lorus Therapeutics Inc), isolated from bovine bile, is a
24 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus"), a biotechnology company focused on the development of novel cancer treatments, and its
Latest LORUS THERAPEUTICS INC Share Price and News. A life sciences company focused on the discovery, research and development of effective
Lorus Therapeutics Inc - Product Pipeline Review - Q1 2011 Lorus Therapeutics Inc - Product Pipeline Review - Q1 2011 Summary Global
As Vice President, Clinical and Medical Affairs at Lorus Therapeutics, Dr. Ely directed the global clinical development of anti-cancer drugs, including leading the
a068170401">LORUS' VIRULIZIN EFFECTIVE AGAINST PANCREATIC TUMORS.. Lorus Therapeutics Inc. (TSE See Tokyo Stock Exchange.
Research and review LORUS THERAPEUTICS INC. jobs. Learn more about a career with LORUS THERAPEUTICS INC. including all recent jobs, hiring trends,
View the basic LRUSF.PK stock chart on Yahoo! Finance. Change the date range , chart type and compare LORUS THERAPEUTICS against other companies.
17 /CNW/ - Herbert Abramson, a director of Lorus Therapeutics Inc. ("Lorus"), announces that he has acquired, indirectly, through Technifund
Get real-time stock quote for Lorus Therapeutics, Inc. LRUSF including chart, current price, historical price, news, financial statements, balance sheet, income
Business Editors TORONTO--(BUSINESS WIRE)--Feb. 12, 2001 Lorus Therapeutics (OTCBB:LORFF)(TSE:LOR.) Position Enhances
TORONTO -- Lorus Therapeutics Inc. ("Lorus") today announced that it has received notice from the United States Patent and Trademark Office
LORUS THERAPEUTICS NEW COM NPV Toronto: LOR.TO,TSE:LOR technical analysis and research for investors, will it rise or fall?, come
TORONTO, ONTARIO Marketwire 113011 Lorus Therapeutics Inc. TSX LOR Lorus or the Corporation, a biopharmaceutical company
Download Historical Stock Quotes for Lorus Therapeutics Inc. [TSX,LOR] in a range of formats. LOR, Lorus Therapeutics Inc. 01/11/2012
TORONTO, ONTARIO, Feb 22, 2011 (MARKETWIRE via COMTEX News Network ) -- Lorus Therapeutics Inc. (TSX: LOR) ("Lorus"),
LRUSF Lorus Therapeutics Inc - Detailed financial news for LRUSF Lorus Therapeutics Inc., a biopharmaceutical company, focuses on the
Lorus Therapeutics Inc. completed a $32.775 million public offering of units on June 11, 2003. The offering was made in Canada pursuant to a short form
Lorus Therapeutics Inc. insider trading by executives and directors, legally reported insider transactions.
Lorus Therapeutics Provides Corporate Update. Nov 30, 2011 4:00:00 PM. TORONTO, ONTARIO -- (MARKET WIRE) -- 11/30/11 -- Lorus Therapeutics Inc. ( TSX:
Lorus Therapeutics. Acute myeloid leukemia. Toronto, ON. Viventia Biotech. Squamous cell carcinoma of the head and neck. Mississauga, ON. YM Biosciences
Browse a daily summary of experts opinions on stocks and stock investment information.
Results 1 - 20 of 264 6-K, LORUS THERAPEUTICS INC, 08/29/11 (05/31/11). 6-K, LORUS THERAPEUTICS INC, 08/26/11 (08/26/11). SC 13D/A, LORUS
News for Medical Sales & Marketing professionals and Independent Sales Representatives: Lorus Therapeutics Strengthens Its Senior
Tag Archives: Cynapsus Therapeutics . Elekta Instrument, Imaging Dynamics, Lorus THerapeutics, Neurokine Pharmaceuticals, Noveko International, Piramal
Lorus Therapeutics Announces Voluntary Delisting From the NYSE Alternext TORONTO, ONTARIO -- (MARKET WIRE) -- 10/10/08 -- Lorus
LOR, LORUS THERAPEUTICS INC, technical analysis, stock analysis, LOR stock , macd, moving average, analysis, stock, LOR shares.
Lorus Therapeutics Inc. (LRP) Closes Private Placement for Gross Proceeds of $1.66 Lorus Therapeutics Inc. (LRP) Reports Results for Fiscal Year 2010
Lorus Therapeutics, Inc. (Toronto, Canada) has obtained a patent to protect the company's intellectual property involving a lead anticancer
Lorus Therapeutics Inc., Toronto, Ontario, Canada. Address correspondence to: Dr. Ming-Yu Cao and Dr. Yoon Lee, Lorus Therapeutics Inc., 2 Meridian Rd.,
Welcome To The Lorus Therapeutics Inc. HUB On AGORACOM. Edit this title from the Fast Facts Section. Hub Home · Profile · Stock Quotes
April 20, 2009 Lorus Therapeutics Presents New Findings for First-in-class Anticancer Drug Candidate LOR-253 - Scientific Presentation at the
12 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ('Lorus'), a biopharmaceutical company specializing in the development and commercialization of
Lorus Therapeutics stock Price (LRP), Stock Quotes and FREE real time streaming Lorus Therapeutics Stock Charts, company fundamentals, Level 2 Data,
LORUS THERAPEUTICS INC is a privately-held company. LORUS THERAPEUTICS INC is a small organization by revenue. LORUS THERAPEUTICS INC
Get detailed financial information on Lorus Therapeutics Inc. (TSE:LOR) including real-time stock quotes, historical charts & financial news, all for free!
View key statistics about Lorus Therapeutics, including where Lorus Therapeutics employees worked before they joined or where they went after they left.
Lorus Therapeutics announces initiation of colon cancer trial with GTI-2040 in cooperation with the U.S. National Cancer Institute. -Novel drug combination
Lorus Therapeutics Inc. (Lorus) (TSX: LOR)(AMEX: LRP), 09:00:59. TORONTO, June 19 /PRNewswire-FirstCall/ -- Lorus Therapeutics Inc.
Lorus Therapeutics' LOR-253 and. BioMarin Pharmaceuticals' BMN-110 both entered phase I trials this quarter and offer interesting innovative approaches in
Exhibit 99.1 News release via Canada NewsWire, Toronto 416-863-9350 Attention Business/Financial Editors: Lorus Therapeutics reports third
Antisense Therapeutics Ltd: background and business model; Strategic technology partnerships Dr Jim Wright, Chief Executive Officer, Lorus Therapeutics.
Find out the latest news headlines for LORUS THERAPEUTICS INC. (LOR.TO).
Biotech / Medical: Lorus Therapeutics Inc. Posts: 279 | Member SubjectMarks: 3 | No Bans | Board Shortcut: SI Sentiment for IMTUF: Insufficient votes
TORONTO, ONTARIO-- - Lorus Therapeutics Inc. , a biopharmaceutical company specializing in the research and development of
Lorus Therapeutics Inc. is a biopharmaceutical company focused on the research and development of pharmaceutical products and
Lorus Therapeutics Inc. has entered into a five-year agreement with AVI BioPharma Inc. to evaluate and codevelop antisense drugs for cancer
Lorus Therapeutics Inc. company research & investing information. Find executives and the latest company news.
TORONTO, ONTARIO, Nov 08, 2011 (MARKETWIRE via COMTEX) -- Lorus Therapeutics Inc. /quotes/zigman/51038 CA:LOR -18.18% ("Lorus")
News for Medical Sales & Marketing professionals and Independent Sales Representatives: Lorus Therapeutics Announces Exclusive
Free Lorus Therapeutics Stock charts (AMEX:LRP). Historical, Intraday and Live Lorus Therapeutics charts with more than 80 charting studies and tools.
See what employees say it's like to work at Lorus Therapeutics. Salaries, reviews, and more - all posted by employees working at Lorus Therapeutics.
TPC - Dingwall and Lorus Therapeutics Inc (en francais). At the rate this is going, ex-Liberal Cabinet Minister David Dingwall is going to be
Working for Lorus means contributing to the progress of science and the
TORONTO, ONTARIO-- - Lorus Therapeutics Inc. , a biopharmaceutical company specializing in the research and development of pharmaceutical products and.
Craig Sibley, Select Therapeutics; Michael Abrams, AnorMED Inc. Michael Hope Bioniche Life Sciences Inc. Graham Strachan, Chairman, Lorus Therapeutics
Browse by: INVENTOR · PATENT HOLDER · PATENT
Lorus Therapeutics Inc. is a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the
Previously she was a member of the Executive Management team at Lorus Therapeutics with responsibility for licensing transactions, acquisitions, and research
Lorus Therapeutics Inc (LOR) - Financial and Strategic SWOT Analysis Review Summary Lorus Therapeutics Inc. (Lorus) is a
Results 1 - 20 of 210 Form, (Filer), Received ( Period ). 6-K, LORUS THERAPEUTICS INC, 12/05/11 ( 12/02/11). 6-K, LORUS THERAPEUTICS INC, 12/02/11
Do not invest in Lorus Therapeutics, Inc (LRUSF) stock before you read this free research report on the company.
Webcast Alert: Lorus Therapeutics Presentation at Informed Investors Biotechnology/ Healthcare Forum to be Webcast on Thurs., Feb. 17, 2005
Clinical Study builds on corporate decision to focus on leukemia indications for GTI-2040 - TORONTO, June 19 /CNW/ - Lorus Therapeutics Inc.
TORONTO, March 1 CNW - Lorus Therapeutics Inc. ( Lorus ) (TSX LOR AMEX LRP), a biopharmaceutical company specializing in the research and
Message Boards Settings Lorus Therapeutics Inc. Search : in. Lorus Therapeutics Inc. board, Stocks L category, Stocks (A to Z) category, All Yahoo! Message
Lorus Therapeutics Inc. is a pharmaceutical company focused on the development of cancer therapies. Lorus' goal is to capitalize on its pre-clinical, clinical a
Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of
Lorus Therapeutics Inc-Therapeutic Competitors Report includes a business summary, tabular representation of the number and percentage of
Kyowa Hakko Kirin; Ligand Pharmaceuticals; Lorus Therapeutics
Dalton Chemical Laboratories Inc. (the Company) is pleased to announce that it has signed an agreement with Lorus Therapeutics to manufacture its lead
Stockhouse Group - Lorus Therapeutics ($LORT) - Overview.
Lorus Therapeutics, a biopharmaceutical company, has announced extension of a cooperative research program with the US National Cancer
Lorus Therapeutics Inc. (New) Aktie (WKN A1CZ5P / ISIN CA5441923052) - Aktueller Kurs, Charts und Nachrichten.
Income from Discontinued Operations data for Lorus Therapeutics: industry ranking, historical trend, and competitor comparison.
Lorus Therapeutics Reports Results for Fiscal Year 2011. Posted by MarketWatch (press release) - August 26th, 2011 ("Lorus" or the "Company") a
Lorus Therapeutics Inc. (Lorus), incorporated on September 5, 1986, is a biopharmaceutical company focused on the discovery, research and development of
Get in touch with Lorus Therapeutics Inc a Supplier in Toronto, ON. The address is 2 Meridian, the phone number is 416-798-1. Get key information at
Exhibit 99.1 NEWS RELEASE Lorus Therapeutics Enrolls First Patient in Phase I Clinical Study of Anti.
Business Editors/Health & Medical Writers TORONTO--(BUSINESS WIRE)-- March 22, 2000 Philippe G. Lacaille, chair and chief executive
(businesspress24) - TORONTO, ONTARIO -- (Marketwire) -- 11/30/11 -- Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Corporation"),
Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the Lorus Therapeutics Inc.'s recent press releases are available
Lorus Therapeutics Inc. Nektar Therapeutics; Neurex Corporation (now Elan Corporation); Neuronyx, Inc. Nosan Corporation; Noscira S.A.; NovaDel Pharma,
30, 2011) - Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the discovery,
Lorus Therapeutics Inc. announced today that its subsidiary GeneSense Technologies, Inc. has signed an exclusive multinational license
It is being developed by Lorus Therapeutics (formerly Imutec Pharma) for the treatment of various cancers and had completed phase II clinical trials in Canada
LORUS THERAPEUTICS INCSEC FILINGS. View all filings and insider trading for LORUS THERAPEUTICS INC.
GTI-2040 (Lorus Therapeutics, Canada) is an antisense oligonucleotide to the R2 subunit downregulating its expression. In preclinical studies, GTI-2040 has
Lorus Therapeutics, Inc., 7100 Woodbine Avenue, Suite 215, Markham, Ontario, L3R Virulizin(R) (registered trademark of Lorus Therapeutics, Inc.) is a novel
The previous two weeks witnessed a flurry of investment activity, including the filing of final prospectuses by each of Lorus Therapeutics and Atrium Innovations
Lorus Therapeutics Inc. (TSX: LOR) (“Lorus”), a biopharmaceutical company specializing in the discovery, research and development of
Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock
TORONTO, ONTARIO-- - Lorus Therapeutics Inc. , a biopharmaceutical company specializing in the discovery and development of
TORONTO, ONTARIO--(Marketwire - April 22, 2009) - Lorus Therapeutics Inc. ( TSX: LOR) ("Lorus"), a biopharmaceutical company specializing
Sponsor: Lorus Therapeutics. Collaborator: Ohio State University. Information provided by: Lorus Therapeutics. ClinicalTrials.gov Identifier
Lorus Therapeutics isn't talking nonsense, they're talking antisense. The biotechnology firm is developing cancer drugs using antisense technology, which
Results 1 - 10 of 50 Directory of patents owned by Lorus Therapeutics (50
Lorus Therapeutics IncTSX/Alpha:LORview on OTC Markets Group Inc - OTCQB » · Help. Symbol Lookup. No Matches were found for. Additional matches for .
Lorus Therapeutics Inc company information, data and profile. Benchmark the business against its key industry competitors.
Research and Markets: Lorus Therapeutics Inc. - Product Pipeline Report Available Now for Review. - Business Wire - November 09, 2007
Dr. Yoon Lee is Vice President - Research of Lorus Therapeutics Inc. Dr. Lee has Mr. Herbert Abramson is Independent Director of Lorus Therapeutics Inc.,
iCo Therapeutics Inc. Lorus Therapeutics. NoAb Biodiscoveries. Jennerx Inc. MDS Nordion. YM Biosciences Inc. Merck Research Laboratories (USA)
TORONTO, July 09, 2008 PRNewswire-FirstCall - Lorus Therapeutics Inc. ( Lorus or the Corporation ), a biopharmaceutical company
Lorus Therapeutics Announces Dramatic Anti-Tumor Results For GTI 2040 - GTI 2040 demonstrates complete regressions in in vivo combination studies -
Lorus Therapeutics Files Final Prospectus for Rights Offering to Shareholders. TORONTO, June 27 /CNW/ - Lorus Therapeutics Inc. (TSX: LOR,
Lorus Therapeutics published a research article by investigators at Ohio State University (OSU) demonstrating that Lorus' lead cancer drug
Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and
Lorus Therapeutics, Inc.: Lorus Therapeutics Inc. is a pharmaceutical company focused on the development of cancer therapies. Lorus' goal is to capitalize on its
TORONTO, ONTARIO--(Marketwire - May 13, 2010) - Lorus Therapeutics Inc. ( TSX:LOR)(OTCBB:LRUSF) ("Lorus" or the "Company"),
Herbert Abramson, du conseil d'administration Lorus Therapeutics (LOR), a mis la Herbert Abramson Acquires Additional Shares of Lorus Therapeutics Inc. .
Lorus Therapeutics Announces Positive Result in its Phase II Clinical Study of LOR-2040 in Acute Myeloid Leukemia (AML). Tuesday
Lorus Therapeutics has reported that its Phase II clinical trial in refractory and relapsed acute myeloid leukemia, or AML, with LOR-2040 in
Rescend PressReleases by Lorus Therapeutics Inc. Lorus Therapeutics Reports First Quarter Results for Fiscal 2012 · Lorus Therapeutics
Lorus Therapeutics Announces Inclusion In TSE 300. - Business Wire - April 25, 2000 - April 25, 2000 - Business Editors TORONTO--(BUSINESS WIRE)--April
lorus therapeutics inc, Find your work among the 195 jobs about lorus therapeutics inc, Jobs about consulting canada inc, accenture inc.
Market Wire - Lorus Therapeutics Announces Publication on LOR-2040 Lorus Therapeutics Inc. (TSX: LOR) ("Lorus"), a biopharmaceutical company
Lorus Therapeutics Inc., Toronto, Ontario, Canada. Requests for reprints: Mario Huesca, Lorus Therapeutics Inc., 2 Meridian Road, Toronto,
Results 131 - 140 of 253 Protiva Biotherapeutics Inc., Welichem Biotech Inc., Allon Therapeutics Inc., Network Immunology Inc., Resverlogix Corp., Lorus
Lorus Therapeutics Inc - 6-K - For 7/12/07 - EX-99.1 - Report of a Foreign Private Issuer - Seq. 2 - Material Change Report - Accession Number
Lorus Therapeutics Inc. (TSX: LOR), a biopharmaceutical company specializing in the research and development of pharmaceutical products
Get detailed financial information on Lorus Therapeutics Inc. (USA) (PINK:LRUSF ) including real-time stock quotes, historical charts & financial news, all for free!
TORONTO Jan. 22 / Lorus Therapeutics Inc. Mr. Korth has previously held senior financial and business developmen Mr. Korth brings
Lorus Therapeutics Inc. (LRP) Wall Street Analyst Forum September 10, 2008 9: 00 AM ET. Gerry Scott. My name is Gerry Scott, I am President
Pipl profiles tagged Lorus Therapeutics. Find the person you're looking for and related people.
NEWS RELEASE Lorus Therapeutics Presents Positive Data From Nonclinical Toxicity Studies on Lead Cancer Drug at Major Conference
Lorus Therapeutics Inc. is a biopharmaceutical company focused on the discovery, research and development of effective anticancer therapies. The Company is
Lorus Therapeutics (formerly GeneSense Technologies) is developing GTI-2501, directed against the R1 component of ribonucleotide
Post-doctoral Research Fellow, LORUS THERAPEUTICS INC job - TORONTO - LORUS THERAPEUTICS. Post-doctoral Research Fellow,
Lorus Therapeutics reviews. A free inside look at company reviews and salaries posted anonymously by employees.
Lorus Therapeutics Announces Allowance of United States Patent for Lead Antimicrobial Small Molecule - MarketWatch. ("Lorus")
TORONTO, ONTARIO, May 03, 2011 (MARKETWIRE via COMTEX News Network) -- Lorus Therapeutics Inc. (TSX: LOR) ("Lorus"),
Lorus Therapeutics Inc., a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies
Lorus Therapeutics Inc. (Lorus) (TSX: LOR)(AMEX: LRP), a biopharmaceutical company specializing in the research and development of
Lorus Therapeutics Inc. announced that the United States Patent and Trademark Office has allowed a new patent for the Company's lead clinical stage cancer
Lorus Therapeutics Inc Product Pipeline Review Q4 2010 Summary Global Market Direct s pharmaceuticals report, Lorus Therapeutics Inc - Product
Company profile, information and contact info for Lorus Therapeutics Inc. - 2 Meridian Rd, Toronto, ON from ProFile Canada, Canada's most trusted Business
menafn: Lorus Therapeutics Announces AllowanceAustralian Patent for Clinical Cancer Drug LOR-253TORONTO, ONTARIO, Sep 27, 2011
LRP - Lorus Therapeutics Inc - SocialPicks. Lorus Therapeutics Announces Receipt of Milestone Payment and Extension of Exclusive License Agreement for
Imutec Pharma, Inc. has changed its name to Lorus Therapeutics, Inc., representing the culmination of a corporate turnaround over the last
Lorus Therapeutics Inc - Product Pipeline Review - H2 2011 Summary Global Market Direct's pharmaceuticals report,
“TORONTO, July 31 /CNW/ - The Board of Directors of Lorus Therapeutics Inc. (“ Lorus”) announced that Dr. Raafat Fahim has resigned as
Up to date analysis of Lorus Therapeutics (LRUSF.PK) and its stock by hedge fund managers and industry experts. Find out what Lorus Therapeutics is saying
The key companies studied in this report are Antisense Pharma GmbH, Lorus Therapeutics, Isis Pharmaceuticals, Alfacell Corporation, Genta Incorporated,
29 /CNW/ - Notification of 2008 Annual and Special Meeting of Shareholders event:Lorus Therapeutics Inc. (AMEX: LRP) (TSX: LOR) 2008
Name: